Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $1.02 USD
Change Today +0.0232 / 2.33%
Volume 100.2K
As of 8:10 PM 08/4/15 All times are local (Market data is delayed by at least 15 minutes).

alexza pharmaceuticals inc (ALXA) Snapshot

Open
$1.04
Previous Close
$1.00
Day High
$1.10
Day Low
$1.00
52 Week High
08/7/14 - $4.90
52 Week Low
07/9/15 - $0.80
Market Cap
19.8M
Average Volume 10 Days
41.0K
EPS TTM
$-2.27
Shares Outstanding
19.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ALEXZA PHARMACEUTICALS INC (ALXA)

alexza pharmaceuticals inc (ALXA) Related Businessweek News

No Related Businessweek News Found

alexza pharmaceuticals inc (ALXA) Details

Alexza Pharmaceuticals, Inc., a pharmaceutical company, focuses on the research, development, and commercialization of proprietary products for the acute treatment of central nervous system conditions worldwide. The company’s product candidates are based on a proprietary technology, the Staccato system, which vaporizes an excipient-free drug to form a condensation aerosol that, when inhaled, allows for rapid systemic drug delivery. It offers ADASUVE (Staccato loxapine) inhalation powder for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults. The company also engages in developing AZ-002 (Staccato alprazolam) for treating patients with acute repetitive seizures, as well as in Phase 2a study for patients with epilepsy; and AZ-007 (Staccato zaleplon) for the treatment of insomnia in patients who have difficulty falling asleep, including patients who awake in the middle of the night and have difficulty falling back asleep. It has collaboration agreement with Grupo Ferrer Internacional S.A. The company was formerly known as Alexza Molecular Delivery Corporation and changed its name to Alexza Pharmaceuticals, Inc. in July 2005.Alexza Pharmaceuticals, Inc. was incorporated in 2000 and is based in Mountain View, California.

81 Employees
Last Reported Date: 03/13/15
Founded in 2000

alexza pharmaceuticals inc (ALXA) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $535.6K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $315.0K
Executive Vice President of Research & Develo...
Total Annual Compensation: $290.0K
Compensation as of Fiscal Year 2014.

alexza pharmaceuticals inc (ALXA) Key Developments

Alexza Pharmaceuticals Receives Non-Compliance Notice From NASDAQ

On June 19, 2015, Alexza Pharmaceuticals, Inc. received a notice from the Nasdaq Stock Market (NASDAQ) indicating that Alexza’s common stock no longer meets the continued listing requirement as set forth in NASDAQ Rule 5550(b)(2) based on the market value of Alexza’s listed securities for the preceding 30 business days. The minimum market value of listed securities for continued listing on the Nasdaq Capital Market is $35 million. Under NASDAQ Rule 5810(c)(3)(C), Alexza has a 180 calendar day grace period from the date of the Notice to regain compliance by meeting the continued listing standard. The continued listing standard will be met if the market value of Alexza’s listed securities closes at $35 million or more for a minimum of 10 consecutive business days during such grace period. If Alexza is unable to regain compliance during the 180 calendar day grace period and receives a delisting determination from NASDAQ it may, at that time, request a hearing to remain on The Nasdaq Capital Market, which request will ordinarily suspend such delisting determination until a decision by NASDAQ subsequent to the hearing. There can be no assurance that Alexza will be successful in maintaining its listing of the Common Stock on The Nasdaq Capital Market. This could impair the liquidity and market price of the Common Stock. In addition, the delisting of the Common Stock from a national exchange could materially adversely affect Alexza’s access to capital markets, and any limitation on market liquidity or reduction in the price of the Common Stock as a result of that delisting could adversely affect Alexza’s ability to raise capital on terms acceptable to Alexza, or at all.

Alexza Amends ADASUVE® Commercial Partnership Agreements with Grupo Ferrer Internacional, S.A. and Teva Pharmaceutical Industries Ltd

Alexza Pharmaceuticals Inc. announced that it has updated and amended its ADASUVE® (Staccato® loxapine) commercial partnerships with Grupo Ferrer Internacional, S.A. and Teva Pharmaceutical Industries Ltd. Ferrer is Alexza's commercial partner for ADASUVE in the European Union, Latin America, the Commonwealth of Independent States and other countries in Europe. Teva is Alexza's commercial partner for ADASUVE in the United States. Ferrer and Alexza Agreement Amendment: Alexza's Manufacturing Obligations: Alexza and Ferrer have agreed to identify more suitable long-term solutions for future ADASUVE manufacturing. Alexza's current ADASUVE manufacturing obligations are to be suspended for a period of time. During the manufacturing suspension period, Alexza and Ferrer will evaluate internal and possible external (third party) manufacturing capabilities. Ferrer's Right to Manufacture: Ferrer and Alexza have agreed that Ferrer will have the option to manufacture ADASUVE at its facilities. If Ferrer chooses to exercise its option, it will be granted ADASUVE manufacturing rights for the Ferrer territories, including an option to manufacture certain additional Staccato products for the Ferrer territories. MAA Transfer to Ferrer: Alexza will transfer the EU Marketing authorization for ADASUVE (MAA), to Ferrer. The MAA transfer includes the responsibilities for the ongoing post-approval clinical studies (the PASS and DUS studies), a future Phase 3 study in adolescents, as well as ongoing pharmacovigilance responsibilities. Milestone Payment Elimination: In consideration for taking on additional responsibilities, the specific milestone payments for first commercial sales in Russia, Brazil and Turkey have been eliminated. Territory and Technology Expansion: Ferrer will gain ADASUVE registration and commercialization rights for Middle East and North Africa (MENA), Korea, Philippines, and Thailand territories. In addition, Ferrer will have the option to develop and commercialize additional Staccato products for the Ferrer territories, with certain rights outside of the current Ferrer territory, in consideration for royalties to Alexza. Teva and Alexza Agreement Amendment: Alexza's Manufacturing Obligations: Alexza and Teva have agreed to identify more suitable long-term solutionsfor future ADASUVE manufacturing. Alexza's current ADASUVE manufacturing obligations are to be suspended for a period of time. During the manufacturing suspension period, Alexza and Teva will evaluate internal and possible external (third party) manufacturing capabilities. Modification of Teva's Commercial Obligations: Alexza and Teva have agreed to adjust certain of Teva's commercial diligence obligations related to ADASUVE for a period of time. Teva will continue to use commercially reasonable efforts to commercialize ADASUVE in the U.S., be responsible for all related regulatory and clinical activities, and will continue to be responsible for royalties and milestone payments on the U.S. sales of ADASUVE. Modification to Teva note: The maturity note will be extended for a time equal to the duration of manufacturing suspension period. No interest will accrue on the Teva note during the manufacturing suspension period. During the manufacturing suspension period Alexza plans to work with its commercial partners to find the most efficient path for future ADASUVE manufacturing and assure ADASUVE supplies for current and new markets.

Alexza Pharmaceuticals Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Alexza Pharmaceuticals Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported revenue of USD 705,000 against USD 2,166,000 a year ago. Loss from operations was USD 13,003,000 against USD 8,803,000 a year ago. Net loss was USD 404,000 or USD 0.02 per basic and diluted share against USD 10,735,000 or USD 0.62 per basic and diluted share a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALXA:US $1.02 USD +0.0232

ALXA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alkermes PLC $70.25 USD -0.08
Aradigm Corp $7.56 USD +0.15
Dr Reddy's Laboratories Ltd 4,177 INR +15.35
Durect Corp $2.36 USD -0.05
Endo International PLC $85.11 USD -1.88
View Industry Companies
 

Industry Analysis

ALXA

Industry Average

Valuation ALXA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.8x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALEXZA PHARMACEUTICALS INC, please visit www.alexza.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.